Literature DB >> 19183417

Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice.

S Thunberg1, T Neimert-Andersson, Q Cheng, F Wermeling, U Bergström, L Swedin, S-E Dahlén, E Arnér, A Scheynius, M C I Karlsson, G Gafvelin, M van Hage, H Grönlund.   

Abstract

BACKGROUND: Defined particles carrying tightly bound allergens at high density have been suggested as alternatives in allergy vaccination. Carbohydrate based particles (CBP), sized 2 microm, provide a platform for covalent coupling of allergens.
OBJECTIVE: To investigate the mechanisms of antigen presentation by CBP, as well as cellular and humoral responses after vaccination with the major cat allergen Fel d 1, covalently coupled to CBP.
METHODS: Mice (n = 10/group) were subcutaneously vaccinated with CBP-rFel d 1, CBP or phosphate buffer saline (PBS) before sensitization with rFel d 1 and challenged with cat dander extract. Fluorescent and (75)Se-radiolabeled tracking of allergens and particles were performed with flow cytometry and whole-body autoradiography. Humoral, cellular and regulatory immune responses were analyzed by ELISA and flow cytometry. Cytokines were measured in bronchoalveolar lavage fluid and splenocyte cultures.
RESULTS: CBP-rFel d 1 prevented induction of airway inflammation and induced allergen-specific T-cell anergy. CBP-rFel d 1 also induced rapid IgM and IgG1-responses compared with soluble rFel d 1. Particles were phagocytosed by antigen-presenting cells and transported to draining lymph nodes and spleen. Moreover, antigen coupled to CBP remained longer at the injection site compared with alum.
CONCLUSIONS: Covalent coupling of rFel d 1 to CBP induces rapid antibody production, prevents induction of allergic immune responses and systemic allergen spreading. Thus, CBP comprise several attractive adjuvant features for use in allergy vaccination. CLINICAL IMPLICATIONS: Prolonged allergen exposure through covalent coupling to particles suitable for phagocytosis, provides an adjuvant for safer and efficient allergy vaccination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19183417     DOI: 10.1111/j.1398-9995.2008.01905.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  8 in total

1.  Glycoproteomic analysis of seven major allergenic proteins reveals novel post-translational modifications.

Authors:  Adnan Halim; Michael C Carlsson; Caroline Benedicte Madsen; Stephanie Brand; Svenning Rune Møller; Carl Erik Olsen; Sergey Y Vakhrushev; Jens Brimnes; Peter Adler Wurtzen; Henrik Ipsen; Bent L Petersen; Hans H Wandall
Journal:  Mol Cell Proteomics       Date:  2014-11-11       Impact factor: 5.911

Review 2.  Therapies for allergic inflammation: refining strategies to induce tolerance.

Authors:  Cezmi A Akdis
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 3.  New vaccines for Mammalian allergy using molecular approaches.

Authors:  Marianne van Hage; Gabrielle Pauli
Journal:  Front Immunol       Date:  2014-03-14       Impact factor: 7.561

Review 4.  New treatments for allergen immunotherapy.

Authors:  Mübeccel Akdis
Journal:  World Allergy Organ J       Date:  2014-09-24       Impact factor: 4.084

Review 5.  Nanoparticle-allergen complexes for allergen immunotherapy.

Authors:  Gabriella Di Felice; Paolo Colombo
Journal:  Int J Nanomedicine       Date:  2017-06-19

6.  Design, production and immunomodulatory potency of a novel allergen bioparticle.

Authors:  Véronique Gomord; Virginie Stordeur; Anne-Catherine Fitchette; Elizabeth D Fixman; Guy Tropper; Lorna Garnier; Réjean Desgagnes; Sébastien Viel; Julie Couillard; Guillaume Beauverger; Sylvain Trepout; Brian J Ward; Ronald van Ree; Loic Faye; Louis-P Vézina
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

Review 7.  New approaches to transcutaneous immunotherapy: targeting dendritic cells with novel allergen conjugates.

Authors:  Richard Weiss; Sandra Scheiblhofer; Yoan Machado; Josef Thalhamer
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-12

Review 8.  Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon.

Authors:  Isabella Pali-Schöll; Douglas J DeBoer; Claudia Alessandri; Ahmed Adel Seida; Ralf S Mueller; Erika Jensen-Jarolim
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.